Trial
NCT00824538
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
National Cancer Institute (NCI)
Condition
Breast Cancer
Intervention
sunitinib malate
Why stopped
Closed prematurely due to emerging data on toxicity and competing trials.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-05